6 results about "Allogeneic graft" patented technology

Provided herein are formulations for treating bone graft materials prior to implantation. Treating the bone graft materials with the formulations disclosed herein can restore the physiological and biochemical characteristics of bone. The bone graft can be a bone allograft. Also provided herein are methods for preparing the formulations and methods for preparing a bone graft for transplantation.

Disclosed herein includes a method for treating antibody-mediated kidney allograft rejection, comprising treating a subject determined to suffer from antibody-mediated kidney allograft rejection more than 6 months after transplantation by administering an anti-CD38 antibody or antigen-binding fragment thereof (e.g., daratumumab, felzartamab, or isatuximab) to the subject; extracting cell-free DNA from a blood, plasma, serum or urine sample collected from the subject after conclusion of the treatment; quantifying an amount of donor-derived cell-free DNA, a percentage of donor-derived cell-free DNA out of total cell-free DNA, or both, in the extracted DNA; and retreating the subject with an anti-CD38 antibody or antigen-binding fragment thereof if the amount of donor-derived cell-free DNA, the percentage of donor-derived cell-free DNA out of total cell-free DNA, or both, exceed one or more threshold values.

Rapid recovery with extended ultra-oxygenated preservation (REUP) can ethically and cost-effectively improve recovery and transplant outcomes for donation after circulatory death (DCD) allografts. REUP can include a portable system, method, and specialized ultra-oxygenated solution(s). The portable system includes a flush circuit and at least one cannula connected to the DCD allograft for flushing the ultra-oxygenated solution into the in-situ DCD allograft. The flush circuit can include at least one reservoir for the ultra-oxygenated solution, a temperature control device, a pressure regulation system, optionally an oxygenator, and tubing for connecting components. The system is noted as easily portable and cost effective for use in many conditions, including environments where traditional recovery systems cannot be used. The methods and solution can be specialized depending on donor demographic information, previous surgeries, and / or allograft type.

Bladder cancer primarily affects older adults, with radical surgery often leading to significant complications due to the use of bowel tissue for bladder reconstruction. Provided herein is a new approach using cryopreserved tissue from cadaveric vessels that avoids these complications. This new method makes surgery safer and recovery quicker, reducing hospital stays and improving patients' quality-of-life. This disclosed method is a major advancement in treating muscle-invasive bladder cancer, offering minimal side effects and a faster return to normal life.

A method of predicting the development of chronic lung allograft dysfunction (CLAD) in lung transplant patients using N-myc-interactor (NMI) as a biomarker and associated treatment thereof is presented. Also presented is a method of reducing the risk of CLAD by administering a therapeutic agent capable of increasing NMI in the patient. NMI is a critical regulator of epithelial-to-mesenchymal transition (EMT) and an important precursor to development of CLAD. NMI expression is reduced in CLAD patients and can be used as an early diagnostic biomarker to predict the development of CLAD. NMI can also be used as a drug target for a therapeutic to increase expression of NMI and treat chronic lung disease such as CLAD. Therapeutics comprising NMI protein or NMI gene can be used as potential treatments for chronic lung diseases such as CLAD.

Disclosed herein includes a method for assessing a lung transplant, comprising extracting cfDNA from a blood sample of a lung transplant recipient; preparing a sequencing library from the extracted cell-free DNA and performing high-throughput sequencing on the sequencing library; quantifying an amount of donor-derived cell-free DNA and / or a percentage of donor-derived cell-free DNA; quantifying an amount of one or more inflammatory mediators in a blood sample or a bronchoalveolar lavage sample of the lung transplant recipient and / or a performance of the lung transplant recipient in one or more physiological tests; and performing a multi-modal assessment to determine the presence or absence of chronic lung allograft dysfunction (CLAD) in the lung transplant recipient.